RxDoctor Payments Data

Mary Gilmer, MD

Foot and Ankle Surgery · Birmingham, ALNPI 1760616924

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (58.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Arthrex at 37.8% of the total. Reporting peaked in 2022 at $3,733 and has fallen 83.7% since, to $607 in 2024.

$8,239in general payments, 2019–2025

Across 67 payments — averaging $122.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$3K
  • Zimmer Biomet$2K
  • Prime Surgical, LLC$2K
  • Paragon 28, Inc.$1K
  • Medshape, Inc.$131
  • Medical Device Business Services, Inc.$122
  • plus $522 from 9 others

What the payments were for

  • Travel & lodging$4,82259%
  • Food & beverage$2,21627%
  • Education$1,20015%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Arthrex26$3,115
Zimmer Biomet13$1,544
Prime Surgical, LLC3$1,540
Paragon 28, Inc.7$1,263
Medshape, Inc.1$131
Medical Device Business Services, Inc.1$122
Aroa Biosurgery Incorporated1$120
Trice Medical, Inc.2$96
Johnson & Johnson(2 entities)3$88
Abbott4$63
Stryker2$57
DJO, LLC1$53
Amgen1$19
ERMI LLC1$16
Orthofix Medical, Inc.1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,239 in reported general payments places this provider in the 65th percentile of 40 foot and ankle surgery providers in Alabama.

See all foot and ankle surgery providers in Alabama

Medicare billing

Part B allowed, 2024
$121,448
Medicare patients
178
Services billed
1,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban26$7,520
Methylprednisolone89$867
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen76$865
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen80$615
Gabapentin30$259
Pregabalin17$190
Celecoxib13$164
Acetaminophen-CodeineAcetaminophen With Codeine14$151
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim24$140
Doxycycline Hyclate16$132
Tramadol Hcl25$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$88$7,52026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 40 foot and ankle surgery providers in Alabama.

Other foot and ankle surgery in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →